{"url_path":"/sec/pstv/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1095981/0001193125-26-226978-index.html","accession_number":"0001193125-26-226978","cik":"0001095981","ticker":"PSTV","issuer_name":"PLUS THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1095981/0001193125-26-226978-index.html","primary_entity_key":"0001095981","primary_entity_name":"PLUS THERAPEUTICS, INC."},"word_count":100,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nOn May 12, 2026, the Company filed a Certificate of Correction (the “Certificate of Correction”) to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Amendment”) that was previously filed on April 1, 2026. The Certificate of Amendment erroneously stated the number of authorized shares of common stock, par value $0.001 per share, of the Company (“Common Stock”) as 200,000,000 (two hundred million).\n\nAs corrected by the Certificate of Correction, the total number of authorized shares of Common Stock is two billion (2,000,000,000).\n\n \n\n \n\n34\n\n[Table of Contents](#table_of_contents)"}